Isocitrate dehydrogenase (IDH) inhibitorFDA-approvedInvestigational
Ivosidenib
How it works
Blocks the IDH2 protein, which is involved in the growth and survival of cancer cells in certain types of leukemia.
Cancer types
Leukemia— IDH1-mutated AML
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 10 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Study Examines Ivosidenib and Azacitidine for AML Patients | Leukemia | phase-3 | — | Source → |
| Testing Ivosidenib and Venetoclax for IDH1 Mutated Hematologic Malignancies | Leukemia | phase-1 | — | Source → |
| New Study Compares Effectiveness of Two Leukemia Treatments | Leukemia | phase-3 | Treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). | Source → |
| New Study Compares Effectiveness of Leukemia Treatments | Leukemia | meta-analysis | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.